Non-alcoholic fatty liver disease and hepatitis C infection

Minerva Gastroenterologica e Dietologica

Volumn 52, Issue 2, 2006, Pages 135-143

  Bondini, S ^a   Younossi, Z M ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Hepatitis C; Infections; Non alcoholic fatty liver disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ADIPOCYTOKINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; AMIODARONE; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; BETAINE; CORTICOSTEROID DERIVATIVE; CYTOKINE; ESTROGEN DERIVATIVE; METFORMIN; NIFEDIPINE; RIBAVIRIN; SALICYLIC ACID DERIVATIVE; URSODEOXYCHOLIC ACID;

APOPTOSIS; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIET; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; EXERCISE; EXTRACELLULAR MATRIX; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; REVIEW; STELLATE CELL; TREATMENT RESPONSE; WEIGHT REDUCTION;

FATTY LIVER; HEPATITIS C; HUMANS;

EID: 33646851743     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Sarbah, SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125-43.
2. Alter JM, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
3. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35:746-52.
4. Seef L, Hoofnagle JH. National institutes of health, consensus development conference: manage hepatitis C. Hepatology 2002;36:51-2.
5. Stader D, Wright T, Thomas D, Seef L. Diagnosis, management and treatment of hepatitis C. Hepatology 2004;39:1147-71.
6. Fried MW, Shiffmann ML, Reddy KR. Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
7. Goodman ZD Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81.
8. Giusti G, Pasquale G, Galante D, Russo M, Sardaro C, Gallo C et al. Clinical and histological aspects of chronic HCV infection and cirrhosis. Hepatogastroenterology 1993;40:365-9.
9. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic Experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
10. Falck-Ytter Y, Younossi ZM, Marchesini G, AcCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
11. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
12. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002;35:497-9.
13. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
14. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
15. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004;53:1020-23.
16. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004;35:196-9.
17. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J et al. Cryptogenic cirrhosis and posttransplant nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801.
18. Ong JP, Younossi ZM. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin Liv Dis 2005;9:617-34.
19. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
20. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000.
21. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Sem Liver Dis 2004;24:399-413.
22. Fernandez-Real JM, Ricart W. insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrin Rev 2003;24:278-301.
23. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005;166:1655-69.
24. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002;122:1529-32.
25. Sanyal AJ, Contos MJ, Sterlig RK, Luketic VA, Shiffman ML, Stravitz RT et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of metabolic syndrome. Am J Gastroenterol 2003;98:2064-71.
26. Sanyal AJ. Review article: non-alcoholic fatty liver disease and hepatitis C - risk factors and clinical implications. Aliment Pharmacol Ther 2005;22 (Suppl 2):48-51.
27. Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ et al. Liver steatosis in chronic hepatitis C: a morphologic sign suggesting infection with genotype 3. Histopathology 2001;39:119-24.
28. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G et al. Hepatocyte steatosis is a cytopatic effect of hepatitis C virus genome 3. J Hepatol 2000;33:106-15.
29. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
30. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
31. Younossi ZM, McCuollough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004;38:705-9.
32. Lonardo A, Adinolfi L, Carulli N, Ruggero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-97.
33. Kumar D, Farrell GC, Fung C, George J. hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002;36:1266-72.
34. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997;78:1527-31.
35. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed non-alcoholic fatty liver disease. Liver 2001;21:266-71.
36. National Institutes of Health. Third report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). NIH publication 1-3670, 2001.
37. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005;41:82-7.
38. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
39. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine amino-transferase, fasting insulin and quality of life. Gut 2004;53:413-9.
40. Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinemia- diabetes-cancer link for preventive efforts. Eur J Cancer Prev 1998;7:89-107.
41. El-Serag H, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001;96:2462-7.
42. Kumar D, Farrel GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol 2005;20:1395-400.
43. Powell EE, Jonsson JR, Clouston AD. Steatosis as a cofactor for other diseases. Hepatology 2005;42:5-13.
44. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-5.
45. Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997;50:401-6.
46. Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005;22:71-3.
47. Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001;34:314-20.
48. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-43.
49. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for liver injury. Hepatology 2004;39:1230-8.
50. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44.
51. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-8.
52. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-8.
53. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of Type 2 Diabetes Mellitus among Persons with Hepatitis C Virus Infection in the United States. Ann Int Med 2000;133:592-9.
54. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001;35:279-83.
55. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in non-cirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000;75:355-9.
56. Bressler BL, Giundi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
57. McCullough AJ. Obesity and its nurturing effect on hepatitis C. Hepatology 2003;38:557-9.
58. Walsh MJ, Jonsson JR, Richardson MM, Lipka G, Purdie D, Clouston A et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of SOCS-3 in patients with chronic hepatitis C, viral genotype 1. Gut 2005; Epub ahead of print.